0.1 Why this issue matters

0.1.1 Cervical cancer is the second most common cancer among Indian women.
0.1.2 It affects 1.25 lakh women annually and causes around 75,000 deaths each year.
0.1.3 Preventive vaccination could significantly reduce both disease burden and mortality.

0.2 What the Swedish study shows

0.2.1 Sweden introduced a school-based HPV vaccination programme.
0.2.2 The study tracked multiple birth cohorts (1989–2000) over time.
0.2.3 It found a reduction in precancerous cervical lesions even among unvaccinated women.

0.3 Meaning of herd protection

0.3.1 Herd protection occurs when vaccination reduces virus circulation in the population.
0.3.2 This indirectly protects unvaccinated individuals.
0.3.3 The Swedish data demonstrates a strong herd-protective effect.

0.4 Evidence across cohorts

0.4.1 Women born between 1989–1992 received subsidised vaccination with 25% coverage.
0.4.2 Those born 1993–98 accessed catch-up vaccination with 55% coverage.
0.4.3 The 1999–2000 cohort, with 80% coverage, showed the largest reduction in precancerous lesions.

0.5 Why coverage levels matter

0.5.1 Herd protection becomes significant when coverage is high and widespread.
0.5.2 Experts recommend 90% coverage among girls.
0.5.3 Even 70% coverage can still provide meaningful population-level protection.

0.6 Relevance for India

0.6.1 India is considering HPV vaccination as a public health strategy.
0.6.2 The Swedish experience shows school-based programmes are cost-effective.
0.6.3 Herd protection is crucial in settings where full coverage may be difficult initially.

0.7 Limits of current evidence

0.7.1 There is no direct data yet on herd immunity from India.
0.7.2 Evidence comes from countries like Australia and the UK, where HPV vaccines are established.
0.7.3 Reduction in actual cancer incidence takes longer than reduction in precancerous lesions.

0.8 Time lag in cancer prevention

0.8.1 HPV vaccination prevents infection, not existing disease.
0.8.2 Visible decline in cervical cancer cases may take several years.
0.8.3 Early indicators include reduced high-grade precancerous lesions.

0.9 Why early vaccination is critical

0.9.1 Vaccination is most effective before sexual debut.
0.9.2 Target age group is 9–14 years, as followed in school-based models.
0.9.3 This ensures protection before HPV exposure.